Global Respiratory Syncytial Virus (RSV) Therapeutics Market Key Insights Reveal Steady CAGR of 11.7% during Forecast 2017-2025

Published on : May 28, 2018

Albany, New York, May 28, 2018: In a recent study, it has been found that RSV or respiratory syncytial virus is very common among people of all ages and it can create bronchiolitis and pneumonia in many cases. Market Research Hub (MRH) has publicized a fresh study titled “Respiratory Syncytial Virus (RSV) Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025” to its vast database, which provides crucial information on the impact of recent market trends and developments on the growth of the market. This 176-page research study states that rise in prevalence of RSV infection among infants and the increasing interest of different biotechnology companies to develop various recombinant drugs to treat RSV infection are likely to fuel the global respiratory syncytial virus (RSV) therapeutics market rapidly.

To elaborate further, the study takes a close look at its current market overview covering historical data from 2015 and offers future forecast until the end of 2025. In addition, the global respiratory syncytial virus therapeutics market, evaluating market performance in terms of revenue, followed by analysis of key trends, drivers, and restraints witnessed in the global market. In order to understand the geographical occurrence of the market, the report studies market’s performance in North America, Europe, Asia Pacific, Latin America and Middle East & Africa. According to the study key highlights, the global respiratory syncytial virus (RSV) therapeutics market was valued at US$ 841.4 Mn in 2016 in terms of revenue and is anticipated to reach more than US$ 2100.0 Mn by 2025, expanding at a CAGR of 11.7% from 2017 to 2025.

Study Key Highlights

RSV, which causes infection of the lungs and breathing passages, is a major cause of respiratory illness in young children and is one of the most common reasons for hospital visits among infants and children. It is reported to be the common cause of pneumonia and bronchiolitis in children as well as adults. Due to this, for companies involved in manufacturing drugs have started to find an effective therapeutic method to treat RSV infection.

Further, the study offers detailed segmentation of global respiratory syncytial virus (RSV) therapeutics market based on drugs type, dosage form, and distribution channel. By drug type, the study includes Palivizumab, Ribavirin and others. By dosage form, these drugs can be used by Oral, and Injectable form.  Among the drugs type studied, the palivizumab segment is estimated to account for a leading share of the global market during the forecast period.

In terms of geography, swelling prevalence of RSV infection among infants and the rise in awareness about the effect of the infection are likely to drive the market in North America. In the near future, the market in Europe and the Asia Pacific is predictable to gain market share.

At last, the competitive strategies of various companies operating in the respiratory syncytial virus (RSV) therapeutics market are also highlighted. Presently, major companies mentioned in the study include F. Hoffmann-La Roche Ltd., AstraZeneca plc, ReViral Ltd., Merck & Co., Inc., Gilead Sciences, Inc., AbbVie, Inc., Valeant Pharmaceuticals International, Inc., GlaxoSmithKline plc., and Teva Pharmaceutical Industries Ltd.

Request a Sample with TOC in a PDF format :

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top